Debiopharm implements Genialis software to advance the discovery of AI-based biomarkers
Genialis Expressions empowers drug development teams to make confident decisions by unifying workflows and standardizing omics data for clarity and enterprise-level comparability across studies
Genialis, the RNA biomarker company, today announced that Swiss-based biopharmaceutical company Debiopharm has deployed the Genialis™ Expressions software platform within its cloud infrastructure to support biomarker discovery and multiomics data analysis. The agreement extends the companies’ multi-year collaboration and gives Debiopharm access to Genialis’ integrated technology for raw data processing and AI-driven biomarker modeling.
“Genialis Expressions solves one of our most persistent challenges: relying on different vendors and workflows to process our omics data, which makes it extremely difficult to compare datasets from different studies,” said Frederico Braga, Head of Digital and IT at Debiopharm. “By establishing a centralized, in-house platform, Genialis Expressions gives us a single standardized pipeline, ensuring consistency across all omics datasets and enabling true comparability across studies.”
During development, therapeutic and diagnostic programs generate biological and clinical data over long periods of time and from many different sources, such as multiple CROs and clinical trial sites. Still, using that information to get clear answers about whether a drug or test is likely to succeed remains a major challenge, especially as readouts from cell lines, mouse and organoid models, and clinical trials are evaluated using different criteria. Genialis Expressions provides the unifying foundation that makes these diverse, longitudinal inputs useful and comparable, delivering standardized, model-ready molecular outputs within a secure cloud environment. Expressions also serves as an entry point into the broader Genialis software ecosystem, which provides comprehensive AI-based modeling and the development of biology-driven biomarker algorithms. This modular, full-stack approach brings coherence to biomarker discovery efforts and delivers new, interpretable insights that can be applied throughout a drug’s development lifecycle and expanded to additional targets and programs as needs evolve.
“Bikemark discovery has traditionally been conducted in an ad hoc manner, with different teams generating and analyzing data at different stages of development. This fragmentation makes it difficult to paint a clear, consistent picture that translates from experimental systems to human studies where it really matters,” said Rafael Rosengarten, PhD, CEO of Genialis. “Our software is like connective tissue to that entire process. By focusing on standardization and harmonization of both molecular and clinical data, we can much more easily learn from new evidence as it arises and build predictive algorithms that span the entire development lifecycle of a drug.”
Genialis Expressions previously worked with Roche Sequencing Solutions and Thermo Fisher Scientific, and is used by leading pharmaceutical, biotechnology and diagnostic companies, as well as leading academic and clinical research organizations around the world. In November 2025, Genialis and Debiopharm jointly presented a poster at ESMO AI 2025 on the development of a clinically relevant biology-based machine learning predictor for response to the WEE1 inhibitor Debio 0123 in combination with carboplatin (CB). Future updates, including publications and presentations, are planned.
Visit www.genialis.com for more information about Genialis, Expressions, ResponderID, krasID or the Supermodel.
For more information about Debiopharm’s expertise, pipeline or portfolio investment companies, visit www.debiopharm.com.
Media contacts
Andrea Vuturo
Vuturo Group for Genius
[email protected]
+1-415-689-8414
View the source version on businesswire.com: https://www.businesswire.com/news/home/20260111177128/en/
